.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Deloitte
Queensland Health
Covington
Argus Health
Dow
Merck
Mallinckrodt
Express Scripts
Cantor Fitzgerald

Generated: September 21, 2017

DrugPatentWatch Database Preview

ELIQUIS Drug Profile

« Back to Dashboard

Which patents cover Eliquis, and what generic Eliquis alternatives are available?

Eliquis is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-two patent family members in forty countries.

The generic ingredient in ELIQUIS is apixaban. There are twenty-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apixaban profile page.

Summary for Tradename: ELIQUIS

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list76
Clinical Trials: see list38
Patent Applications: see list631
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ELIQUIS at DailyMed

Pharmacology for Tradename: ELIQUIS

Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-002Dec 28, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-002Dec 28, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-002Dec 28, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-002Dec 28, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-002Dec 28, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ELIQUIS

Drugname Dosage Strength RLD Submissiondate
apixabanTablets2.5 mg and 5 mgEliquis12/28/2016

Non-Orange Book Patents for Tradename: ELIQUIS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,188,120Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
8,470,854Lactam-containing compounds and derivatives thereof as factor XA inhibitors► Subscribe
6,673,810 Imidazo-heterobicycles as factor Xa inhibitors► Subscribe
7,005,435Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,995,172Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,989,391Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,960,411Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,531,535Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,691,846Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,858,616 Nitrogen containing heterobicycles as factor Xa inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ELIQUIS

Country Document Number Estimated Expiration
Poland373299► Subscribe
HungaryS1300014► Subscribe
European Patent Office3017811► Subscribe
Norway2011021► Subscribe
Hungary228195► Subscribe
Australia2008207537► Subscribe
CroatiaP20040280► Subscribe
Cyprus1117434► Subscribe
South Korea100909141► Subscribe
China104744461► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ELIQUIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
888Luxembourg► Subscribe91888, EXPIRES: 20260518
1427415/01Switzerland► SubscribeFORMER OWNER: BRISTOL-MYERS SQUIBB COMPANY, US
5 5011-2011Slovakia► SubscribeFORMER OWNER: BRISTOL-MYERS SQUIBB COMPANY, US
2011012,C1427415Lithuania► SubscribePRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005, 0110518
0110017 00045Estonia► SubscribePRODUCT NAME: ELIQUIS - APIKSABAAN; REG NO/DATE: C(2011)3595 18.05.2011
90029-7Sweden► SubscribePRODUCT NAME: APIXABAN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV; REG. NO/DATE: EU/1/11/691/001-005 20110518
C0042France► SubscribePRODUCT NAME: APIXABAN, EVENTUELLEMENT SOUS LA FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/691/001 20110518
2011012Lithuania► SubscribePRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005 20110518
3Finland► Subscribe
C/GB11/042United Kingdom► SubscribePRODUCT NAME: APIXABAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/11/691/001 20110520; UK EU/1/11/691/002 20110520; UK EU/1/11/691/003 20110520; UK EU/1/11/691/004 20110520; UK EU/1/11/691/005 20110520
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Citi
Johnson and Johnson
Merck
Colorcon
Dow
Express Scripts
Cipla
Cerilliant
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot